Findings

What do systematic reviews say?

42 questions · 42 findings · 1 reviews · Epilepsy · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 21 · 50%Very low 5 · 11.9%Low 9 · 21.4%Moderate 7 · 16.7%High 0 · 0%

Paroxetine vs doxepin

> 50% reduction in depressive symptoms · people with epilepsy and depression

Paroxetine showed no clear difference in > 50% reduction in depressive symptoms compared with doxepin (moderate certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 1.16 [0.88, 1.52]
1 study · 67 participants
Moderate

Amitriptyline vs nomifensine

Seizure frequency · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Amitriptyline vs nomifensine

Treatment withdrawal · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Amitriptyline vs nomifensine

Cognitive function · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Amitriptyline vs nomifensine

Quality of life · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Amitriptyline vs nomifensine

Adverse effects · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Venlafaxine vs no treatment

> 50% reduction in depressive symptoms · people with epilepsy and depression

Venlafaxine may leads to higher > 50% reduction in depressive symptoms compared with no treatment (low certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 3.25 [1.19, 8.9]
1 study · 64 participants
Low

Venlafaxine vs no treatment

Depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Venlafaxine vs no treatment

Seizure frequency · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Venlafaxine vs no treatment

Treatment withdrawal · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Venlafaxine vs no treatment

Cognitive function · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs doxepin

Depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Moderate

Venlafaxine vs no treatment

Quality of life · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Venlafaxine vs no treatment

Adverse effects · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Sertraline vs cognitive behavioural therapy

> 50% reduction in depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Sertraline vs cognitive behavioural therapy

Depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 117 participants
Moderate

Sertraline vs cognitive behavioural therapy

Seizure frequency · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low

Sertraline vs cognitive behavioural therapy

Treatment withdrawal · people with epilepsy and depression

Sertraline showed no clear difference in withdrawals compared with cognitive behavioural therapy (moderate certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 1.26 [0.64, 2.46]
1 study · 140 participants
Moderate

Sertraline vs cognitive behavioural therapy

Cognitive function · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Sertraline vs cognitive behavioural therapy

Quality of life (QOLIE‐89) (1‐ to 3‐month periods) · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Moderate